Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats

Journal of Pharmaceutical Sciences

Volumn 98, Issue 11, 2009, Pages 4391-4401

  Liu, Yitong ^a   Hao, Haiping ^a   Xie, Hongguang ^b   Lv, Hua ^c   Liu, Changxiao ^d   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b San Francisco School of Medicine   (United States)

^c Shanghai PharmaExplorer   (China)

^d TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

BBR; CYPs; Enzyme kinetics; Metabolic clearance; Microsomes; Pharmacokinetics; UGTs

Indexed keywords

BERBERINE; BEROLINE; BEROLINE GLUCURONIDE; CYTOCHROME P450; DEMETHYLENEBERBERINE; DEMETHYLENEBERBERINE GLUCURONIDE; DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B1; JATRORRHIZINE; JATRORRHIZINE GLUCURONIDE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME SUBSTRATE; LIVER MICROSOME METABOLISM; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 70349641500     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21721     Document Type: Article

References (36)

1. Amin AH, Subbaiah TV, Abbasi KM. 1969. Berberine sulfate: Antimicrobial activity, bioassay, and mode of action. Can J Microbiol 15:1067-1076.
2. Kettmann V, Kosfalova D, Jantova S, Cernakova M, Drimal J. 2004. In vitro cytotoxicity of berberine against HeLa and L1210 cancer cell lines. Pharmazie 59:548-551.
3. Gudima SO, Memelova LV, Borodulin VB, Pokholok DK, Mednikov BM, Tolkachev ON, Kochetkov SN. 1994. Kinetic analysis of interaction of human immunodeficiency virus reverse transcriptase with alkaloids. Mol Biol (Mosk) 28:1308-1314.
4. Vollekova A, Kost'alova D, Kettmann V, Toth J. 2003. Antifungal activity of Mahonia aquifolium extract and its major protoberberine alkaloids. Phytother Res 17:834-837.
5. Tran QL, Tezuka Y, Ueda JY, Nguyen NT, Maruyama Y, Begum K, Kim HS, Wataya Y, Tran QK, Kadota S. 2003. In vitro antiplasmodial activity of antimalarial medicinal plants used in Vietnamese traditional medicine. J Ethnopharmacol 86:249-252.
6. Kupeli E, Kosar M, Yesilada E, Husnu K, Baser C. 2002. A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish Berberis species. Life Sci 72:645-657. (Pubitemid 35441232)
7. Rackova L, Majekova M, Kost'alova D, Stefek M. 2004. Antiradical and antioxidant activities of alkaloids isolated from Mahonia aquifolium. Structural aspects. Bioorg Med Chem 12:4709-4715.
8. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344-1351. (Pubitemid 40022716)
9. Cheng Z, Pang T, Gu M, Gao AH, Xie CM, Li JY, Nan FJ, Li J. 2006. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta 1760:1682-1689.
10. Kim TS, Kang BY, Cho D, Kim SH. 2003. Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, deviates CD4+ T cells from a Th2 to a Th1 response. Immunology 109:407-414. (Pubitemid 36783267)
11. Tsai PL, Tsai TH. 2004. Hepatobiliary excretion of berberine. Drug Metab Dispos 32:405-412.
12. Zuo F, Nakamura N, Akao T, Hattori M. 2006. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos 34:2064-2072. (Pubitemid 44837767)
13. Qiu F, Zhu Z, Kang N, Piao S, Qin G, Yao X. 2008. Isolation and identification of urinary metabolites of berberine in rats and humans. Drug Metab Dispos 36:2159-2165.
14. Hong JY, Pan JM, Ning SM, Yang CS. 1989. Molecular basis for the sex-related difference in renal N-nitrosodimethylamine demethylase in C3H/HeJ mice. Cancer Res 49:2973-2979.
15. Okado-Matsumoto A, Fridovich I. 2001. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J Biol Chem 276:38388-38393. (Pubitemid 37371188)
16. Hao H, Wang G, Cui N, Li J, Xie L, Ding Z. 2007. Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr Drug Metab 8:137-149. (Pubitemid 46218680)
17. Taura K, Naito E, Ishii Y, Mori MA, Oguri K, Yamada H. 2004. Cytochrome P450 1A1 (CYP1A1) inhibitor alpha-naphthoflavone interferes with UDP-glucuronosyltransferase (UGT) activity in intact but not in permeabilized hepatic microsomes from 3-methylcholanthrene-treated rats: Possible involvement of UGT-P450 interactions. Biol Pharm Bull 27:56-60. (Pubitemid 41656673)
18. Zhao LZ, Huang M, Chen J, Ee PL, Chan E, Duan W, Guan YY, Hong YH, Chen X, Zhou S. 2006. Induction of propranolol metabolism by Ginkgo biloba extract EGb 761 in rats. Curr Drug Metab 7:577-587. (Pubitemid 44226586)
19. Peng FC, Lin Wu SW. 2002. Metabolism of territrem a in liver microsomes from male wistar rats: 3. Cytochrome p-450 isoforms catalyzing tra metabolism. J Toxicol Environ Health A 65:2163-2175.
20. Stresser DM, Dehal SS, Kupfer D. 1996. Ring hydroxylation of [o-3H]methoxychlor as a probe for liver microsomal CYP2B activity: Potential for in vivo CYP2B assay. Anal Biochem 233:100-107. (Pubitemid 26036367)
21. Liu YT, Hao K, Liu XQ, Wang GJ. 2006. Metabolism and metabolic inhibition of gambogic acid in rat liver microsomes. Acta Pharmacol Sin 27:1253-1258. (Pubitemid 44411008)
22. Zhou JQ, Tang ZQ, Zhang JN, Tang JC. 2006. Metabolism and effect of para-toluene-sulfonamide on rat liver microsomal cytochrome P450 from in vivo and in vitro studies. Acta Pharmacol Sin 27:635-640.
23. Mandlekar SV, Rose AV, Cornelius G, Sleczka B, Caporuscio C, Wang J, Marathe PH. 2007. Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates. Xenobiotica 37:923-942. (Pubitemid 47482947)
24. Zhang H, Davis CD, Sinz MW, Rodrigues AD. 2007. Cytochrome P450 reaction-phenotyping: An industrial perspective. Expert Opin Drug Metab Toxicol 3:667-687. (Pubitemid 351320636)
25. Yu L, Lu S, Lin Y, Zeng S. 2007. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol 73:1842-1851.
26. Narayanan R, LeDuc B, Williams DA. 2004. Glucuronidation of haloperidol by rat liver microsomes: Involvement of family 2 UDP-glucuronosyltransferases. Life Sci 74:2527-2539. (Pubitemid 38317117)
27. Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. 2004. Predicting human drug glucuronidation parameters: Application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
28. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. 2006. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos 34:449-456.
29. D'Andrea V, Perez LM, Sanchez Pozzi EJ. 2005. Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin- glucuronide. Life Sci 77:683-692. (Pubitemid 40726355)
30. Tian H, Ou J, Strom SC, Venkataramanan R. 2005. Activity and expression of various isoforms of uridine diphosphate glucuronosyltransferase are differentially regulated during hepatic regeneration in rats. Pharm Res 22:2007-2015. (Pubitemid 41821579)
31. Mano Y, Usui T, Kamimura H. 2008. Species differences in inhibition potential of nonsteroidal antiinflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans. J Pharm Sci 97:2805-2810.
32. Radominska-Pandya A, Bratton S, Little JM. 2005. A historical overview of the heterologous expression of mammalian UDP-glucuronosyltransferase isoforms over the past twenty years. Curr Drug Metab 6:141-160. (Pubitemid 40394342)
33. Elsherbiny ME, El-Kadi AO, Brocks DR. 2008. The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci 11:147-159.
34. Pan JF, Yu C, Zhu DY, Zhang H, Zeng JF, Jiang SH, Ren JY. 2002. Identification of three sulfate-conjugated metabolites of berberine chloride in healthy volunteers' urine after oral administration. Acta Pharmacol Sin 23:77-82. (Pubitemid 34073273)
35. Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY. 2002. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol 91:193-197.
36. Uchaipichat V, Galetin A, Houston JB, Mackenzie PI, Williams JA, Miners JO. 2008. Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol 74:1152-1162.